Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19
Status:
Completed
Trial end date:
2021-05-06
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of a single dose of subcutaneous injections of 180 ug of
Peginterferon Lambda-1a, compared with placebo in reducing the duration of viral shedding of
SARS-CoV-2 virus in patients with uncomplicated COVID-19 disease.